The estimated Net Worth of Deval L Patrick is at least $3.88 Milion dollars as of 6 June 2024. Mr. Patrick owns over 11,593 units of Global Blood Therapeutics stock worth over $3,252,042 and over the last 9 years he sold GBT stock worth over $48,044. In addition, he makes $581,995 as Director at Global Blood Therapeutics.
Sign up
Mr. Patrick GBT stock SEC Form 4 insiders trading
Deval has made over 15 trades of the Global Blood Therapeutics stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 11,593 units of GBT stock worth $794,005 on 6 June 2024.
The largest trade he's ever made was exercising 42,379 units of Global Blood Therapeutics stock on 6 July 2018 worth over $907,758. On average, Deval trades about 3,333 units every 71 days since 2015. As of 6 June 2024 he still owns at least 47,482 units of Global Blood Therapeutics stock.
You can see the complete history of Mr. Patrick stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Deval Patrick biography
Deval L. Patrick J.D. serves as Director of the Company. Mr. Patrick previously served as a member of our Board of Directors from April 2015 to November 2019. Mr. Patrick is the founder and chairman of TogetherFUND, a political action committee working to elevate the values of generational responsibility and servant leadership in public service. From April 2015 to December 2019, Mr. Patrick served as a managing director of Bain Capital, LP, and from January 2007 to January 2015, Mr. Patrick served as the governor of Massachusetts. Prior to his tenure in government, from 2000 to 2004, Mr. Patrick served as the executive vice president and general counsel at The Coca-Cola Company. Prior to that, he served as vice president and general counsel at Texaco Inc., from 1998 to 1999. He was a partner in two Boston law firms and, from 1994 to 1997, served as the Assistant Attorney General of the United States for Civil Rights in the Department of Justice. Mr. Patrick received an A.B. in English and American Literature from Harvard College and a J.D. from Harvard Law School.
What is the salary of Deval Patrick?
As the Director of Global Blood Therapeutics, the total compensation of Deval Patrick at Global Blood Therapeutics is $581,995. There are 16 executives at Global Blood Therapeutics getting paid more, with Ted Love having the highest compensation of $10,097,200.
How old is Deval Patrick?
Deval Patrick is 62, he's been the Director of Global Blood Therapeutics since 2020. There are 5 older and 13 younger executives at Global Blood Therapeutics. The oldest executive at Global Blood Therapeutics Inc. is Willie Brown, 86, who is the Independent Director.
What's Deval Patrick's mailing address?
Deval's mailing address filed with the SEC is TOAST, INC., 333 SUMMER STREET, BOSTON, MA, 02210.
Insiders trading at Global Blood Therapeutics
Over the last 9 years, insiders at Global Blood Therapeutics have traded over $164,753,446 worth of Global Blood Therapeutics stock and bought 255,000 units worth $8,595,265 . The most active insiders traders include Advisors Llcperceptive Life..., Rock Ventures Ii, L.P.Third... a Kevin P Starr. On average, Global Blood Therapeutics executives and independent directors trade stock every 14 days with the average trade being worth of $3,133,144. The most recent stock trade was executed by Nazila Habibizad on 1 October 2022, trading 1,557 units of GBT stock currently worth $106,639.
What does Global Blood Therapeutics do?
Global Blood Therapeutics (GBT) is a biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing treatments that provide hope to underserved patient communities. Founded in 2011, GBT is delivering on its goal to transform the treatment and care of sickle cell disease (SCD), a lifelong, devastating inherited blood disorder. The company has introduced Oxbryta® (voxelotor) tablets, the first FDA-approved treatment that directly inhibits sickle hemoglobin polymerization, the root cause of red blood cell sickling in SCD. GBT is also advancing its pipeline program in SCD with inclacumab, a P-selectin inhibitor in development to address pain crises associated with the disease, and GBT021601 (GBT601), the company's next generation hemoglobin S polymerization inhibitor. In addition, GBT's drug discovery teams are working on new targets to develop the next wave of treatments for SCD.
What does Global Blood Therapeutics's logo look like?
Complete history of Mr. Patrick stock trades at Global Blood Therapeutics, Twilio Inc, American Well Corp a Toast
Global Blood Therapeutics executives and stock owners
Global Blood Therapeutics executives and other stock owners filed with the SEC include:
-
Ted Love,
President, Chief Executive Officer, Director -
Brian Cathers,
Chief Scientific Officer -
Tricia Suvari,
Chief Legal Officer -
Jung Choi,
Chief Business and Strategy Officer -
David Johnson,
Chief Commercial Officer -
Jeffrey Farrow,
Chief Financial Officer -
Dr. Ted W. Love,
Pres, CEO & Director -
Dr. Ted W. Love M.D.,
Pres, CEO & Director -
David L. Johnson,
Chief Commercial Officer -
Jeffrey S. Farrow,
CFO & Principal Accounting Officer -
Jung E. Choi,
Chief Bus. & Strategy Officer -
Dr. Kim Smith-Whitley M.D.,
Exec. VP and Head of R&D -
Patricia Borga Suvari,
Chief Legal Officer & Sec. -
Mark Perry,
Lead Independent Director -
Scott Morrison,
Independent Director -
Wendy Yarno,
Independent Director -
Deval Patrick,
Director -
Glenn Pierce,
Independent Director -
Philip Pizzo,
Independent Director -
Willie Brown,
Independent Director -
Dawn Svoronos,
Independent Director -
Eric Fink,
Chief Human Resource Officer -
Stephanie Yao,
Sr. Director of Corp. Communications & Investor Relations -
Nazila Habibizad,
Exec. VP of Operations -
Dr. Andrej Sali Ph.D.,
Founder & Advisor -
Dr. Matthew P. Jacobson Ph.D.,
Founder & Advisor -
Dr. David R. Phillips,
Founder & Advisor -
Lesley Ann Calhoun,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Ii, L.P.Third...,
-
Michael W Bonney,
Director -
Eleanor Ramos,
Chief Medical Officer -
Kevin P Starr,
Director -
Charles J Homcy,
Director -
Robert I Tepper,
10% owner -
Rock Ventures Ii, L.P.Starr...,
-
Hing Sham,
See Remarks -
Joshua Lehrer Graiwer,
Chief Medical Officer -
Advisors Llcperceptive Life...,
-
Peter Radovich,
See Remarks -
Nazila Habibizad,
See Remarks -
John Schembri,
See Remarks -
Rock Ventures Ii, L.P.Third...,
-
Rock Ventures Iii, L.P.Thir...,
-
Carrie Krehlik,
Chief Human Resources Officer -
Alexis A. Thompson,
Director -
Kim Smith Whitley,
See Remarks